Treatment News : Sofosbuvir and Ribavirin Fare Well Among HIV-HCV Coinfected

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 4, 2013

Sofosbuvir and Ribavirin Fare Well Among HIV-HCV Coinfected

An all-oral, interferon-free, 12- or 24-week regimen of sofosbuvir and ribavirin cured between 67 and 88 percent of those coinfected with HIV and genotypes 1, 2 or 3 of hepatitis C virus (HCV) in a recent advanced trial. Representatives from Gilead Sciences presented findings from the “PHOTON-1” Phase III open-label study of the nucleotide analogue sofosbuvir at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC.

In one arm of the study, 114 coinfected participants with genotype 1 of hep C received 24 weeks of therapy. Seventy-six percent (87) achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).

In another branch of the study, 26 coinfected participants with genotype 2 of hep C and 42 coinfected participants with genotype 3 received 12 weeks of treatment. Eighty-eight percent (23) of the genotype 2 participants and 67 percent (28) of the genotype 3 participants achieved an SVR12.

Three percent of those receiving 24 weeks of therapy discontinued therapy because of adverse side effects, as did 4 percent of those receiving 12 weeks of therapy. The most common side effects were in line with ribavirin’s safety profile, including fatigue, nausea, headache and insomnia.

To read a Gilead release on the trial, click here.

Search: sofosbuvir, coinfected, HIV, hepatitis C, hep C, HCV, genotype, PHOTON-1, SVR, sustained virologic response, Gilead Sciences, 64th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    Drew949
    South Orange County
    California


    Reginaldb06
    Atlanta
    Georgia


    cortaza100
    Chicago
    Illinois


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.